Programmed Death Ligand-1 expression in stage II colon cancer

experiences from a nationwide populationbased cohort

Ann C. Eriksen*, Flemming B. Sørensen, Jan Lindebjerg, Henrik Hager, René dePont Christensen, Sanne Kjær-Frifeldt, Torben F. Hansen

*Kontaktforfatter for dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

45 Downloads (Pure)

Resumé

BACKGROUND: Patients suffering from high risk stage II colon cancer (CC) may benefit from adjuvant onco-therapy, but additional prognostic markers are needed for better treatment stratification. We investigated the prognostic value of Programmed Death Ligand-1 (PD-L1) in a true population-based cohort of patients with stage II CC. METHODS: PD-L1 expression on tumour cells was evaluated by immunohistochemistry in 572 colon cancers. Whole sections from tumour blocks representing the deepest invasive front of the primary tumour were used for analysis. A cut-off of 5% positivity was used for dichotomizing the data. The prognostic value was investigated in Cox proportional hazard models for recurrence-free survival (RFS) and overall survival (OS). RESULTS: Overall, 6% of the tumours were classified as high PD-L1. High PD-L1 was related to female gender (p = 0.028), high malignancy grade (< 0.001), right side localization (p < 0.001) and microsatellite instability (MSI) (p < 0.001). Thirty-one (18%) of the MSI and 4 (1%) of the microsatellite stable tumours were classified as high PD-L1, respectively. PD-L1 expression provided no prognostic value as a single marker. In patients with MSI tumours, high PD-L1 expression had no significant impact regarding OS or RFS. CONCLUSIONS: PD-L1 expression in tumour cells of stage II CC did not provide any prognostic impact, neither in the entire population-based cohort nor in the group of MSI patients. Additional investigations of the immunogenic microenvironment are needed for evaluating the prognostic information in CC.

OriginalsprogEngelsk
Artikelnummer142
TidsskriftBMC Cancer
Vol/bind19
Antal sider9
ISSN1471-2407
DOI
StatusUdgivet - 12. feb. 2019

Fingeraftryk

Colonic Neoplasms
Ligands
Microsatellite Instability
Neoplasms
Proportional Hazards Models
Population

Citer dette

@article{894a11dc19ca441ba6c4f5fe64e9426a,
title = "Programmed Death Ligand-1 expression in stage II colon cancer: experiences from a nationwide populationbased cohort",
abstract = "BACKGROUND: Patients suffering from high risk stage II colon cancer (CC) may benefit from adjuvant onco-therapy, but additional prognostic markers are needed for better treatment stratification. We investigated the prognostic value of Programmed Death Ligand-1 (PD-L1) in a true population-based cohort of patients with stage II CC. METHODS: PD-L1 expression on tumour cells was evaluated by immunohistochemistry in 572 colon cancers. Whole sections from tumour blocks representing the deepest invasive front of the primary tumour were used for analysis. A cut-off of 5{\%} positivity was used for dichotomizing the data. The prognostic value was investigated in Cox proportional hazard models for recurrence-free survival (RFS) and overall survival (OS). RESULTS: Overall, 6{\%} of the tumours were classified as high PD-L1. High PD-L1 was related to female gender (p = 0.028), high malignancy grade (< 0.001), right side localization (p < 0.001) and microsatellite instability (MSI) (p < 0.001). Thirty-one (18{\%}) of the MSI and 4 (1{\%}) of the microsatellite stable tumours were classified as high PD-L1, respectively. PD-L1 expression provided no prognostic value as a single marker. In patients with MSI tumours, high PD-L1 expression had no significant impact regarding OS or RFS. CONCLUSIONS: PD-L1 expression in tumour cells of stage II CC did not provide any prognostic impact, neither in the entire population-based cohort nor in the group of MSI patients. Additional investigations of the immunogenic microenvironment are needed for evaluating the prognostic information in CC.",
keywords = "Colon cancer stage II, Prognostic markers, Programmed death ligand-1, Immunohistochemistry, Predictive Value of Tests, Colonic Neoplasms/diagnosis, Prognosis, B7-H1 Antigen/metabolism, Follow-Up Studies, Humans, Middle Aged, Survival Analysis, Aged, 80 and over, Adult, Population Groups, Aged, Neoplasm Staging, Cohort Studies",
author = "Eriksen, {Ann C.} and S{\o}rensen, {Flemming B.} and Jan Lindebjerg and Henrik Hager and {dePont Christensen}, Ren{\'e} and Sanne Kj{\ae}r-Frifeldt and Hansen, {Torben F.}",
year = "2019",
month = "2",
day = "12",
doi = "10.1186/s12885-019-5345-6",
language = "English",
volume = "19",
journal = "B M C Cancer",
issn = "1471-2407",
publisher = "BioMed Central",

}

Programmed Death Ligand-1 expression in stage II colon cancer : experiences from a nationwide populationbased cohort. / Eriksen, Ann C.; Sørensen, Flemming B.; Lindebjerg, Jan; Hager, Henrik; dePont Christensen, René; Kjær-Frifeldt, Sanne; Hansen, Torben F.

I: BMC Cancer, Bind 19, 142, 12.02.2019.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Programmed Death Ligand-1 expression in stage II colon cancer

T2 - experiences from a nationwide populationbased cohort

AU - Eriksen, Ann C.

AU - Sørensen, Flemming B.

AU - Lindebjerg, Jan

AU - Hager, Henrik

AU - dePont Christensen, René

AU - Kjær-Frifeldt, Sanne

AU - Hansen, Torben F.

PY - 2019/2/12

Y1 - 2019/2/12

N2 - BACKGROUND: Patients suffering from high risk stage II colon cancer (CC) may benefit from adjuvant onco-therapy, but additional prognostic markers are needed for better treatment stratification. We investigated the prognostic value of Programmed Death Ligand-1 (PD-L1) in a true population-based cohort of patients with stage II CC. METHODS: PD-L1 expression on tumour cells was evaluated by immunohistochemistry in 572 colon cancers. Whole sections from tumour blocks representing the deepest invasive front of the primary tumour were used for analysis. A cut-off of 5% positivity was used for dichotomizing the data. The prognostic value was investigated in Cox proportional hazard models for recurrence-free survival (RFS) and overall survival (OS). RESULTS: Overall, 6% of the tumours were classified as high PD-L1. High PD-L1 was related to female gender (p = 0.028), high malignancy grade (< 0.001), right side localization (p < 0.001) and microsatellite instability (MSI) (p < 0.001). Thirty-one (18%) of the MSI and 4 (1%) of the microsatellite stable tumours were classified as high PD-L1, respectively. PD-L1 expression provided no prognostic value as a single marker. In patients with MSI tumours, high PD-L1 expression had no significant impact regarding OS or RFS. CONCLUSIONS: PD-L1 expression in tumour cells of stage II CC did not provide any prognostic impact, neither in the entire population-based cohort nor in the group of MSI patients. Additional investigations of the immunogenic microenvironment are needed for evaluating the prognostic information in CC.

AB - BACKGROUND: Patients suffering from high risk stage II colon cancer (CC) may benefit from adjuvant onco-therapy, but additional prognostic markers are needed for better treatment stratification. We investigated the prognostic value of Programmed Death Ligand-1 (PD-L1) in a true population-based cohort of patients with stage II CC. METHODS: PD-L1 expression on tumour cells was evaluated by immunohistochemistry in 572 colon cancers. Whole sections from tumour blocks representing the deepest invasive front of the primary tumour were used for analysis. A cut-off of 5% positivity was used for dichotomizing the data. The prognostic value was investigated in Cox proportional hazard models for recurrence-free survival (RFS) and overall survival (OS). RESULTS: Overall, 6% of the tumours were classified as high PD-L1. High PD-L1 was related to female gender (p = 0.028), high malignancy grade (< 0.001), right side localization (p < 0.001) and microsatellite instability (MSI) (p < 0.001). Thirty-one (18%) of the MSI and 4 (1%) of the microsatellite stable tumours were classified as high PD-L1, respectively. PD-L1 expression provided no prognostic value as a single marker. In patients with MSI tumours, high PD-L1 expression had no significant impact regarding OS or RFS. CONCLUSIONS: PD-L1 expression in tumour cells of stage II CC did not provide any prognostic impact, neither in the entire population-based cohort nor in the group of MSI patients. Additional investigations of the immunogenic microenvironment are needed for evaluating the prognostic information in CC.

KW - Colon cancer stage II

KW - Prognostic markers

KW - Programmed death ligand-1

KW - Immunohistochemistry

KW - Predictive Value of Tests

KW - Colonic Neoplasms/diagnosis

KW - Prognosis

KW - B7-H1 Antigen/metabolism

KW - Follow-Up Studies

KW - Humans

KW - Middle Aged

KW - Survival Analysis

KW - Aged, 80 and over

KW - Adult

KW - Population Groups

KW - Aged

KW - Neoplasm Staging

KW - Cohort Studies

U2 - 10.1186/s12885-019-5345-6

DO - 10.1186/s12885-019-5345-6

M3 - Journal article

VL - 19

JO - B M C Cancer

JF - B M C Cancer

SN - 1471-2407

M1 - 142

ER -